Ultimately, greater characterization of the pathogenesis and incidence of BM in NTRK fusion-positive NSCLC and the intracranial efficacy of next-generation TRK inhibitors is needed, which may also elucidate our molecular understanding of BM in other NTRK fusion-positive cancers. The gene discussed is NTRK1; the disease is cancer.